Noninvasive colorectal cancer screening tool shows unprecedented detection rates

Mayo Clinic research results presented in NEJM could change colorectal screening practice

2014-03-19

(Press-News.org) ROCHESTER, Minn. — March 17, 2014 — Results of a clinical trial of Cologuard show unprecedented rates of precancer and cancer detection by a noninvasive test. The detection rates are similar to those reported for colonoscopy. The results were published in the March 20 issue of the New England Journal of Medicine (NEJM). Cologuard was co-developed by Mayo Clinic and Exact Sciences.

Cologuard, is a noninvasive sDNA test for the early detection of colorectal precancer and cancer. The Cologuard test is based on a stool sample that is analyzed for DNA signatures of precancer or cancer. The samples are easily collected, mailed from home, requires no bowel preparation, medication restriction or diet change.

The clinical trial, called the DeeP-C study, included 10,000 patients and was designed to determine how well Cologuard detects precancer and cancer. The study also compared Cologuard to the fecal immunochemical test for occult blood (FIT). The study was conducted at 90 medical centers throughout the United States and Canada.

"Cologuard detection rates of early stage cancer and high-risk precancerous polyps validated in this large study were outstanding and have not been achieved by other noninvasive approaches," says the study's author David Ahlquist M.D., a Mayo Clinic gastroenterologist and co-inventor of the Cologuard test. "It is our hope that this accurate and user-friendly test will expand screening effectiveness and help curb colorectal cancer rates in much the same way as regular screening, including genetic testing, has done for cervical cancer."

In the study, all patients received Cologuard, FIT and colonoscopy. Colonoscopy was the reference method. Major findings reported in the study include:

Sensitivity of Cologuard for cancer was 92 percent overall, and 94 percent for the earliest and most curable cancer stages (stages I and II).

Sensitivity was 69 percent for precancerous polyps at greatest risk to progress to cancer (i.e., those containing high-grade dysplasia).

Cologuard detected significantly more cancers and significantly more precancerous polyps than did FIT.

"The most important finding of the study is the high sensitivity of Cologuard for curable stage colorectal cancer, which represents the highest sensitivity of any noninvasive test to date," says Thomas Imperiale, M.D., a Professor of Medicine at Indiana University Medical Center in Indianapolis and a study author. "It is also significant to note that these results were achieved in a robustly conducted multicenter study."

Colorectal cancer is often considered the most preventable, yet least prevented, cancer. Nearly 50 percent of adults age 50 and older have not been screened as recommended and, as a result, colorectal cancer has become the second-leading cause of cancer death in the United States. Colorectal cancer is highly treatable if found early, and it is preventable if the precancerous polyps at greatest risk of progressing can be detected.

"Dr. Ahlquist's work exemplifies our goal at Mayo Clinic, which is the relentless pursuit of innovation aimed to help our patients. This research will transform how we think about colorectal cancer screening going forward," says Vijay Shah, M.D., chair of Mayo Clinic's Division of Gastroenterology and Hepatology.

Cologuard works by testing a patient's stool for altered DNA shed during digestion. Altered DNA is known to occur within colorectal cancers and precancerous polyps. The test also examines the stool for the presence of blood, another possible indicator of colorectal cancer. Combining the data from the stool DNA test and the blood test into a single result provides a comprehensive, powerful screening approach, which is reflected in the study results.

Because of its accessibility and ease of use, researchers hope the test will increase the number of people who will choose to be screened for colorectal cancer. Screening is important because, if cancer is detected early, removing polyps during a colonoscopy can prevent the cancer.

"This test has the potential to bring colon cancer screening to many patients who might otherwise go without any screening," says Kenneth Wang, M.D., a Mayo Clinic gastroenterologist, director of the Advanced Endoscopy Group and president of the American Society for Gastrointestinal Endoscopy. "I'm hopeful that this will increase the number of patients obtaining lifesaving colonoscopy with early detection and removal of precancerous and early cancerous polyps."

Exact Sciences is the co-developer of Cologuard. The company is in the process of seeking approval from the Food and Drug Administration for the use of Cologuard for colorectal cancer screening. The company is scheduled to appear before the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee on March 27.

INFORMATION:

The DeepP-C clinical study was funded by Exact Sciences. Mayo Clinic is an equity investor in Exact Sciences. In relation to Exact Sciences, Dr. Ahlquist is a scientific advisor, research collaborator and inventor of licensed technology.

About Mayo Clinic

Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, http://www.mayoclinic.org and newsnetwork.mayoclinic.org.

MEDIA CONTACT: Brian Kilen, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

ELSE PRESS RELEASES FROM THIS DATE:

New, noninvasive, stool-based colorectal cancer screening test

2014-03-19

(New York, March 19, 2014) – A new, non-invasive, stool-based screening test detected 92% of colorectal cancer (CRC), according to a multicenter trial published online today in the New England Journal of Medicine. The new test, which is not yet approved by the FDA, allows patients to collect a sample at home without the need for bowel preparation or diet restrictions. Unlike other available stool-based CRC screening tests, which rely solely on detecting occult blood in the stool, this new test, called "Cologuard", developed and patented by Exact Sciences, detects both ...

Work shines light on Hox genes responsible for firefly lantern development

2014-03-19

It's difficult to identify a single evolutionary novelty in the animal kingdom that has fascinated and intrigued mankind more than the lantern of the firefly. Yet to this day, nothing has been known about the genetic foundation for the formation and evolution of this luminescent structure. But now, new work from a former Indiana University Bloomington graduate student and his IU Ph.D. advisor offers for the first time a characterization of the developmental genetic basis of this spectacular morphological novelty -- the firefly's photic organ -- and the means by which this ...

Winners and losers in globalization of world's economy, health and education

2014-03-19

Globalization has made the world a better and more equal place for many more people than was the case a few decades ago. However, it has also created two well-defined worlds of poor countries and wealthy nations, according to Vanesa Jordá and José María Sarabia of the University of Cantabria in Spain. In an article published in Springer's journal Applied Research in Quality of Life, they studied the distribution of well-being over the last wave of globalization between 1980 and 2011. Well-being is generally described as the state of being happy, healthy or prosperous. ...

Magnetic behavior discovery could advance nuclear fusion

2014-03-19

ANN ARBOR—Inspired by the space physics behind solar flares and the aurora, a team of researchers from the University of Michigan and Princeton has uncovered a new kind of magnetic behavior that could help make nuclear fusion reactions easier to start. Fusion is widely considered the ultimate goal of nuclear energy. While fission leaves behind radioactive waste that must be stored safely, fusion generates helium, a harmless element that is becoming scarce. Just 250 kilograms of fusion fuel can match the energy production of 2.7 million tons of coal. Unfortunately, it ...

Increased risk of relapse omitting RT in early PET scan negative Hodgkin lymphoma

2014-03-19

Interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial published in the Journal of Clinical Oncology indicates an increased risk of early relapse when omitting radiotherapy in early PET scan negative patients with stage I/II Hodgkin's lymphoma. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these initial findings are maintained over time. Dr. J.M.M. Raemaekers of the Radboud university medical center Nijmegen, The Netherlands, and central coordinator of the study says, "The standard treatment for patients with ...

Study finds forest corridors help plants disperse their seeds

2014-03-19

A forest in South Carolina, a supercomputer in Ohio and some glow-in-the-dark yarn have helped a team of field ecologists conclude that woodland corridors connecting patches of endangered plants not only increase dispersal of seeds from one patch to another, but also create wind conditions that can spread the seeds for much longer distances. The idea for the study emerged from modern animal conservation practices, where landscape connectivity – the degree to which landscapes facilitate movement – is being used to counteract the impacts of habitat loss and fragmentation ...

Inflammation mobilizes tumor cells

2014-03-19

Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich have discovered a novel feedback mechanism that provides a mechanistic link between chronic inflammation and carcinogenesis. Malignant tumors pose a major threat to survival largely because they shed mobile cells that can form secondary tumors in other tissues. This process requires a fundamental change in the character of cells within the primary tumor, insofar as members of a localized cell mass must be converted into actively migrating cells that invade into the surrounding tissue and blood vessels, and ...

IU, Regenstrief study: New noninvasive colorectal cancer screening tool highly accurate

2014-03-19

INDIANAPOLIS -- An Indiana University and Regenstrief Institute study of nearly 10,000 average-risk, asymptomatic men and women from 90 sites across the United States reports that a multi-target stool DNA test -- a new noninvasive colorectal cancer screening tool that has not yet been approved for sale by the Food and Drug Administration -- detects 92.3 percent of colon cancers, compared to only 73.8 percent of cancers detected by a fecal immunochemical test, the most commonly used noninvasive test today. Study results were published online March 19 and in the April ...

Earliest evidence of limb bone marrow in the fin of a 370 million year old fish

2014-03-19

This week in the journal Proceedings of the Royal Society B, a team of French and Swedish researchers present the earliest fossil evidence for the presence of bone marrow in the fin of a 370 million-year-old fish. Long bones, which are found in the limb of tetrapods, are not only important for locomotion and supporting the weight of the body, but also host the bone marrow. The latter plays a major role in haematopoiesis, i.e. the formation of blood cells. In a healthy adult human, about a hundred billion to one trillion new blood cells are produced every day to maintain ...

Internists must play a larger role in managing menopausal symptoms

2014-03-19

New Rochelle, NY, March 19, 2014—The number of menopausal women is projected to reach 50 million by 2020. With changing views on appropriate therapies to control symptoms and new treatments available and on the horizon, most internists lack the core competencies and experience to meet the needs of women entering menopause, according to a provocative Commentary published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website at http://www.liebertpub.com/jwh. The ...

Northwestern Medicine, West Health, Meadows Mental Health Policy Institute collaboration to provide easier access to mental health care

Is therapeutic hypothermia an effective treatment for hypoxic-ischemic encephalopathy, a type of neurological dysfunction in newborns?

New AEM study highlights feasibility of cranial accelerometry device for prehospital detection of large-vessel occlusion stroke

Global experts make sense of the science shaping public policies worldwide in new International Science Council and Frontiers Policy Labs series

[Press-News.org] Noninvasive colorectal cancer screening tool shows unprecedented detection rates
Mayo Clinic research results presented in NEJM could change colorectal screening practice

Noninvasive colorectal cancer screening tool shows unprecedented detection rates

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: